Regulatory · Glossary
FDA bulks list Category 2
Also written: Category 2 bulks list · 503A Category 2 · 503B Category 2
Definition
The FDA bulks lists sort substances compounders may use; Category 2 flags significant safety risks and gets no enforcement discretion.
FDA bulks list category 2 is an interim bucket for substances nominated for 503A or 503B compounding that FDA says may present significant safety risks; those substances do not receive Category 1 enforcement discretion. The label is neither FDA approval nor a final, permanent ban, and the live table can change when nominations move or are withdrawn.
What is the category 1 vs category 2 FDA difference?
The category 1 vs category 2 FDA distinction is about enforcement while FDA evaluates nominated bulk ingredients, not whether a drug is approved. Under the FDA 503A bulks list policy, Category 1 can receive enforcement discretion if every policy condition is met. Category 2 does not. The 503B policy uses the same basic split for outsourcing facilities.
| State | Plain-English meaning | What it does not mean |
|---|---|---|
| Category 1 | FDA has enough nomination information to evaluate the substance and may exercise enforcement discretion during review. | FDA approval or permanent placement on a bulks list. |
| Category 2 | FDA identified potential significant safety risks and may use its general enforcement policies against compounding with the substance. | A clinical verdict on every possible use. |
| Nomination withdrawn | The nominator pulled the request; the substance leaves that active nomination category. | Approval, Category 1 status, or permission to compound. |
Is BPC-157 category 2 now?
BPC-157 is not in the active Category 2 table on FDA’s safety-risk page, current as of April 22, 2026. BPC-157 appears under “nominated but withdrawn,” alongside the safety concerns FDA recorded during its earlier review. Withdrawal changed the nomination’s procedural state; it did not erase those concerns or approve BPC-157.
A BPC-157 category 2 headline from 2023 is therefore incomplete today. By contrast, the same dated page keeps ibutamoren mesylate in Category 2 for both 503A and 503B, while ipamorelin acetate remains Category 2 for 503B even though its 503A nomination was withdrawn. One molecule can carry different rows in the two lanes. Regulatory paperwork does enjoy a footnote.
How should peptide readers use the list?
FDA bulks list category 2 should be read with three checks: the exact substance and route, whether the row applies to 503A or 503B, and the page’s as-of date. “Removed from Category 2” without those details tells only half the story.
The compounding glossary explains the two pharmacy lanes. The regulatory-status hub tracks dated compound status, while the BPC-157 evidence profile separates research evidence from FDA status. A bulks category governs a compounding pathway; it does not grade human efficacy or turn a research chemical into an approved medicine.